Search

Keywords for this news article include: University of Florence, Florence, Italy, Europe, Surgery, Robotics, Men's Health, Prostatectomy, Machine Learning, Health and Medicine, Emerging Technologies, Male Urologic Surgical Procedures. Keywords: Emerging Technologies; Health and Medicine; Machine Learning; Male Urologic Surgical Procedures; Men's Health; Prostatectomy; Robotics; Robots; Surgery EN Emerging Technologies Health and Medicine Machine Learning Male Urologic Surgical Procedures Men's Health Prostatectomy Robotics Robots Surgery 553 553 1 03/23/23 20230305 NES 230305 2023 MAR 5 (NewsRx) -- By a News Reporter-Staff News Editor at Medical Devices & Surgical Technology Week -- Investigators discuss new findings in prostatectomy. [Extracted from the article]

A recent study from the Chinese University of Hong Kong highlights the potential of Lutetium-177-prostate-specific membrane antigen (Lu 177-PSMA) therapy for advanced prostate cancer. The research discusses the promising results of trials using Lu 177-PSMA in different stages of prostate cancer, including metastatic castration-resistant prostate cancer (mCRPC) and localized prostate cancer. The study concludes that Lu 177-PSMA therapy represents a significant advancement in prostate cancer treatment, offering targeted radiation delivery to cancer cells and potentially improving outcomes for patients. [Extracted from the article]

A study conducted at the Chinese University of Hong Kong explored the impact of age on survival outcomes in non-muscle-invasive bladder cancer patients treated with Bacillus Calmette-Guerin (BCG). The research found that younger patients (<=70 years) had better overall survival, cancer-specific survival, and recurrence-free survival compared to older patients (>70 years). Additionally, patients in the younger age group who received adequate BCG treatment showed better outcomes than those in the older age group. The study concluded that older patients who received adequate BCG treatment had similar progression-free survival as younger patients with adequate treatment. [Extracted from the article]

A recent report from Vita-Salute San Raffaele University discusses the challenges of applying randomized controlled trials (RCTs) to real-life scenarios in the treatment of metastatic prostate cancer. RCTs often involve participants who are younger and have better prognoses compared to real-world patients. The PIONEER project aims to evaluate the generalizability of RCT findings by comparing patient characteristics from RCTs to those from population-based databases. The study will rely on observational data from registries, electronic health records, and insurance claims. The objective is to improve cancer-related outcomes and enhance the quality of care for patients with metastatic prostate cancer. [Extracted from the article]

Keywords: Florence; Italy; Europe; Biomarkers; Coronaviridae; Coronavirus; Cytokines; Diagnostics and Screening; Health and Medicine; Inflammation; Intercellular Signaling Peptides and Proteins; Interleukins; Nidovirales; RNA Viruses; Respiratory Tract Diseases and Conditions; Respiratory Tract Infections; Risk and Prevention; SARS; Severe Acute Respiratory Syndrome; Viral; Virology EN Florence Italy Europe Biomarkers Coronaviridae Coronavirus Cytokines Diagnostics and Screening Health and Medicine Inflammation Intercellular Signaling Peptides and Proteins Interleukins Nidovirales RNA Viruses Respiratory Tract Diseases and Conditions Respiratory Tract Infections Risk and Prevention SARS Severe Acute Respiratory Syndrome Viral Virology 1034 1034 1 10/30/23 20231030 NES 231030 2023 OCT 30 (NewsRx) -- By a News Reporter-Staff News Editor at Respiratory Therapeutics Week -- Investigators discuss new findings in Respiratory Tract Diseases and Conditions - Severe Acute Respiratory Syndrome. Sexually active men with previous severe acute respiratory syndrome coronavirus 2 infection and proven recovery from coronavirus disease 2019 were enrolled in a prospective cohort study.". [Extracted from the article]

Moreover, periglandular inflammation was higher in the cores with neoplasia, while stromal inflammation was higher in cores without neoplasia (38.5% vs. 31.1% and 55.4% vs. 63.5% p < 0.01)." Keywords: Cancer; Health and Medicine; Inflammation; Oncology; Prostate Cancer; Prostatic Neoplasms EN Cancer Health and Medicine Inflammation Oncology Prostate Cancer Prostatic Neoplasms 1274 1274 1 03/24/23 20230228 NES 230228 2023 FEB 28 (NewsRx) -- By a News Reporter-Staff News Editor at Cancer Weekly -- New research on prostate cancer is the subject of a new report. Cancer, Health and Medicine, Inflammation, Oncology, Prostate Cancer, Prostatic Neoplasms. [Extracted from the article]